This company listing is no longer active
Aceragen (ACGN) Stock Overview
Aceragen, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare pulmonary and rheumatic diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
ACGN Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Aceragen, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.38 |
| 52 Week High | US$16.00 |
| 52 Week Low | US$0.36 |
| Beta | 1.14 |
| 1 Month Change | -48.99% |
| 3 Month Change | -76.54% |
| 1 Year Change | -95.55% |
| 3 Year Change | -98.96% |
| 5 Year Change | -99.78% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| ACGN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -11.6% | 1.7% | 0.5% |
| 1Y | -95.5% | 27.8% | 23.5% |
Return vs Industry: ACGN underperformed the US Biotechs industry which returned 6.3% over the past year.
Return vs Market: ACGN underperformed the US Market which returned 4.2% over the past year.
Price Volatility
| ACGN volatility | |
|---|---|
| ACGN Average Weekly Movement | 23.7% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ACGN's share price has been volatile over the past 3 months.
Volatility Over Time: ACGN's weekly volatility (24%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 26 | John Taylor | www.aceragen.com |
Aceragen, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare pulmonary and rheumatic diseases in the United States. Its clinical development pipeline includes ACG-701, which is in Phase 2 clinical trial for cystic fibrosis pulmonary exacerbations, as well as for melioidosis; and ACG-801 for farber disease. Aceragen, Inc. has a collaboration and option agreement with Scriptr Global, Inc. to identify, research, and develop gene therapy candidates for the treatment, palliation, diagnosis, or prevention of myotonic dystrophy type 1 and Friedreich’s Ataxia.
Aceragen, Inc. Fundamentals Summary
| ACGN fundamental statistics | |
|---|---|
| Market cap | US$3.20m |
| Earnings (TTM) | -US$41.05m |
| Revenue (TTM) | US$7.33m |
Is ACGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACGN income statement (TTM) | |
|---|---|
| Revenue | US$7.33m |
| Cost of Revenue | US$15.40m |
| Gross Profit | -US$8.06m |
| Other Expenses | US$32.98m |
| Earnings | -US$41.05m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.88 |
| Gross Margin | -110.00% |
| Net Profit Margin | -559.86% |
| Debt/Equity Ratio | 1.3% |
How did ACGN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/08/23 15:27 |
| End of Day Share Price | 2023/08/21 00:00 |
| Earnings | 2023/03/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Aceragen, Inc. is covered by 8 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Ulz | Baird |
| Michael King | Citizens JMP Securities, LLC |
| Matthew Bannon | J.P. Morgan |